Literature DB >> 29434888

AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma.

Guoan Zhang1, Xia Kong2, Meng Wang3, Hongli Zhao4, Sha Han5, Ronghang Hu6, Jian Huang7, Wen Cui1.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is a common cancer in China and certain other parts of the world with a dismal prognosis for affected patients. AXL is a member of the TYRO3-AXL-MER family of receptor tyrosine kinases, and has been revealed to be an important mediator of epithelial-mesenchymal transition (EMT) in several types of cancer. However, to the best of our knowledge, its function in EMT in ESCC cells has not yet been examined. The present study employed two independent ESCC mRNA profile datasets and revealed that AXL is associated with several EMT markers. Gene Set Enrichment Analysis indicated that EMT occurs more in ESCC with high AXL expression. Analysis on another dataset demonstrated further that increased expression of AXL in ESCC is associated with increased migratory ability. Collectively, the results of the present study provide evidence that AXL is a marker for EMT in ESCC.

Entities:  

Keywords:  AXL; epithelial-mesenchymal transition; esophageal squamous cell carcinoma

Year:  2017        PMID： 29434888      PMCID： PMC5774429          DOI： 10.3892/ol.2017.7443

Source DB:  PubMed          Journal:  Oncol Lett        ISSN： 1792-1074            Impact factor:   2.967


  34 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.

Authors:  Fang Wu; Junhe Li; Changchen Jang; Janfeng Wang; Jianping Xiong
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.

Authors:  Jane Antony; Tuan Zea Tan; Zoe Kelly; Jeffrey Low; Mahesh Choolani; Chiara Recchi; Hani Gabra; Jean Paul Thiery; Ruby Yun-Ju Huang
Journal:  Sci Signal       Date:  2016-10-04       Impact factor: 8.192

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 6.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses.

Authors:  Christine Vogel; Edward M Marcotte
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

7.  Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Authors:  Amanda Kirane; Kathleen F Ludwig; Noah Sorrelle; Gry Haaland; Tone Sandal; Renate Ranaweera; Jason E Toombs; Miao Wang; Sean P Dineen; David Micklem; Michael T Dellinger; James B Lorens; Rolf A Brekken
Journal:  Cancer Res       Date:  2015-07-23       Impact factor: 12.701

8.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

Review 9.  TGF-beta-induced epithelial to mesenchymal transition.

Authors:  Jian Xu; Samy Lamouille; Rik Derynck
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

Review 10.  AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

Authors:  Ross A Okimoto; Trever G Bivona
Journal:  Lung Cancer (Auckl)       Date:  2015-04-30
View more
  6 in total

Review 1.  Epithelial-Mesenchymal Plasticity in Tumor Immune Evasion.

Authors:  Riley D Z Mullins; Ananya Pal; Thomas F Barrett; Molly E Heft Neal; Sidharth V Puram
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

2.  Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.

Authors:  Jessica M Konen; B Leticia Rodriguez; Aparna Padhye; Joshua K Ochieng; Laura Gibson; Lixia Diao; Natalie W Fowlkes; Jared J Fradette; David H Peng; Robert J Cardnell; Jeffrey J Kovacs; Jing Wang; Lauren A Byers; Don L Gibbons
Journal:  Cancer Res       Date:  2021-01-05       Impact factor: 13.312

3.  Qigesan inhibits esophageal cancer cell invasion and migration by inhibiting Gas6/Axl-induced epithelial-mesenchymal transition.

Authors:  Lingyu Kong; Xin Lu; Xuanyu Chen; Yunyan Wu; Yushuang Zhang; Huijuan Shi; Jing Li
Journal:  Aging (Albany NY)       Date:  2020-05-20       Impact factor: 5.682

Review 4.  Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.

Authors:  Solange Peters; Luis Paz-Ares; Roy S Herbst; Martin Reck
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

5.  Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC).

Authors:  Pei-Wen Yang; Yu-Cheng Liu; Ya-Han Chang; Ching-Ching Lin; Pei-Ming Huang; Kuo-Tai Hua; Jang-Ming Lee; Min-Shu Hsieh
Journal:  Front Oncol       Date:  2019-11-06       Impact factor: 6.244

6.  Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma.

Authors:  Sha Han; Yequan Wang; Chengyan Ge; Mingtao Gao; Xintong Wang; Feiyu Wang; Lei Sun; Sheng Li; Tingting Dong; Zhen Dang; Wen Cui; Guoan Zhang; Ning Liu
Journal:  Exp Ther Med       Date:  2020-09-02       Impact factor: 2.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.